MARATTO

article · Medical Journal of Zambia

Accelerated CD4+ T-cell recovery following vitamin D supplementation in a virologically suppressed adult living with HIV - A Case Report

2026Open accessUniversity of Zambia

Abstract

Background: Immune non-response despite sustained HIV viral suppression remains a clinical challenge. We report a patient with a prolonged plateau in CD4 count who experienced a marked rise following correction of vitamin D insufficiency. Case presentation: A 48-year-old man with chronic HIV infection, fully adherent to antiretroviral therapy and virologically suppressed for at least two years (2022-2024), developed disseminated osteoarticular tuberculosis involving the left hip and shoulder. After completing prolonged anti- tuberculosis therapy, his viral load remained suppressed (40 copies/mL) but CD4 count plateaued at 426 cells/mm3. Serum 25-hydroxyvitamin D was 25 ng/mL (insufficient). Vitamin D3 60,000 IU weekly was initiated. After six months, CD4 count increased to 1,071 cells/mm3 while viral suppression was maintained, with no change in antiretroviral regimen or other concurrent therapies. Conclusion: Vitamin D supplementation temporally coincided with accelerated CD4 recovery in a virologically suppressed patient with prior poor immunological recovery. Causality cannot be inferred from a single case; controlled studies are required to clarify whether vitamin D repletion benefits immune non-responders.

Research topics

  • Vitamin D Research Studies
  • HIV-related health complications and treatments
  • Pneumocystis jirovecii pneumonia detection and treatment

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.55320/mjz.53.2.855

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.